Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.43 |
| ▸ | NOS1 | P29475 | 5/20 | 0.42 |
| ▸ | NOS3 | P29474 | 3/20 | 0.42 |
| ▸ | NOS2 | P35228 | 3/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | CASP1 | P29466 | 2/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | SLC6A4 | P31645 | 5/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14875929 | 0.84 | NOS1 (0.40) | NOS1NOS3NOS2SLC6A4 | |
| SCHEMBL5190941 | 0.81 | PRKCI (0.54) | NOS1NOS3NOS2ALDH1A1CYP3A4 | |
| SCHEMBL8590051 | 0.81 | SLC6A4 (0.43) | NOS1NOS3NOS2SLC6A4 | |
| SCHEMBL19392511 | 0.79 | SKP2 (0.47) | TAAR1NOS2ALDH1A1CASP1CYP3A4 | |
| SCHEMBL2176041 | 0.79 | ALDH1A1 (0.50) | TAAR1ALDH1A1CASP1CYP3A4TSHR | |
| SCHEMBL5160883 | 0.79 | NOS1 (0.42) | NOS1NOS3NOS2SLC6A4 | |
| SCHEMBL13511895 | 0.79 | MPO (0.55) | TAAR1NOS1NOS3NOS2SLC6A4 | |
| SCHEMBL6498411 | 0.78 | NOS1 (0.52) | TAAR1NOS1TSHRSLC6A4MAPK1 | |
| SCHEMBL12005806 | 0.78 | NOS1 (0.36) | NOS1NOS3NOS2SLC6A4 | |
| SCHEMBL28156915 | 0.78 | TAAR1 (0.46) | TAAR1ALDH1A1CASP1CYP3A4TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8642624-B2 | Substituted alkylamine derivatives and methods of use | AMGEN INC. (US) | 2014-02-04 | — | — | US | disclosed |
| US-20130273004-A1 | SUBSTITUTED ALKYLAMINE DERIVATIVES AND METHODS OF USE | AMGEN INC (US) | 2013-10-17 | — | — | US | disclosed |
| US-8247556-B2 | Method for preparing 6-substituted-7-aza-indoles | AMGEN INC. (US) | 2012-08-21 | — | — | US | disclosed |
| US-20120065185-A1 | SUBSTITUTED ALKYLAMINE DERIVATIVES AND METHODS OF USE | AMGEN INC. (US) | 2012-03-15 | — | — | US | disclosed |
| US-8058445-B2 | Substituted pyridinecarboxamides for the treatment of cancer | AMGEN INC. (US) | 2011-11-15 | — | — | US | disclosed |
| US-7687643-B2 | Process for preparing 3,3-dimethylindolines | AMGEN INC. (US) | 2010-03-30 | — | — | US | disclosed |
| US-7514564-B2 | Substituted amine derivatives and methods of use | AMGEN INC. (US) | 2009-04-07 | — | — | US | disclosed |
| US-20070185171-A1 | Compounds and methods of use | AMGEN INC. | 2007-08-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130273004-A1 | SUBSTITUTED ALKYLAMINE DERIVATIVES AND METHODS OF USE | AADAC, NAT1, PIGO | TAAR1 541/4885NOS1 216/4885NOS3 108/4885 |
| US-20070185171-A1 | Compounds and methods of use | VHL, PGF, PTGIS | TAAR1 4488/4885NOS1 444/4885NOS3 240/4885 |
| US-20120065185-A1 | SUBSTITUTED ALKYLAMINE DERIVATIVES AND METHODS OF USE | AADAC, NAT1, PIGO | TAAR1 541/4885NOS1 216/4885NOS3 108/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.